Advancements in the development of radiopharmaceuticals for nuclear medicine applications in the treatment of bone metastases

Dyer, Michael R.; Jing, Zhenghan; Duncan, Kathleen; Godbe, Jacqueline; Shokeen, Monica

doi:10.1016/j.nucmedbio.2024.108879

Cited by 5 publications

(3 citation statements)

References 130 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The production of sufficient quantities and high quality of new radionuclides for use in nuclear medicine, either for treatment or diagnosis, requires systematic and extensive efforts from the stage of production to their clinical use [ 12 , 41 , 42 ]. Several key steps are crucial to ensuring a steady supply of radionuclides for medical applications, including cyclotron or nuclear reactor production, target material selection, isotope separation, radiopharmaceutical labeling, quality control, radiopharmacy distribution, clinical administration, regulatory compliance, radiation safety measures, patient-specific factors (e.g., health status and age), and diagnostic or therapeutic intent [ 12 , 41 ].…”

Section: Methods For the Detection Of Scandium And Other Radionuclide...mentioning

confidence: 99%

“…There are various other factors that need to be considered in choosing the ideal radionuclide, which can be summarized as follows: (a) Physicochemical properties: type of radiation, decay emission(s), energy of emission, and half-life; (b) The cost of the enriched target material and its recovery process, as well as its stability for long-term supply; (c) Access to available facilities for production and transport to the point of administration, within an acceptable time frame; (d) The cost of production and separation of the produced radionuclide, and (e) The simplicity and speed of the chemical separation method [ 41 , 47 ].…”

Section: Methods For the Detection Of Scandium And Other Radionuclide...mentioning

confidence: 99%

“…The production of new radionuclides for the purpose of producing new and innovative radiopharmaceuticals is a multidisciplinary collaboration between nuclear physicists, radiochemists, engineers, and radiopharmacists, among others [ 41 ]. The first stage in the process is the production, chemical separation, and quality control of the radionuclide.…”

Section: Properties and Effects Of Scandium In The Context Of Nuclear...mentioning

confidence: 99%

See 2 more Smart Citations

Towards Clinical Development of Scandium Radioisotope Complexes for Use in Nuclear Medicine: Encouraging Prospects with the Chelator 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid (DOTA) and Its Analogues

Ioannidis,

Lefkaritis,

Georgiades

et al. 2024

IJMS

View full text Add to dashboard Cite

Scandium (Sc) isotopes have recently attracted significant attention in the search for new radionuclides with potential uses in personalized medicine, especially in the treatment of specific cancer patient categories. In particular, Sc-43 and Sc-44, as positron emitters with a satisfactory half-life (3.9 and 4.0 h, respectively), are ideal for cancer diagnosis via Positron Emission Tomography (PET). On the other hand, Sc-47, as an emitter of beta particles and low gamma radiation, may be used as a therapeutic radionuclide, which also allows Single-Photon Emission Computed Tomography (SPECT) imaging. As these scandium isotopes follow the same biological pathway and chemical reactivity, they appear to fit perfectly into the “theranostic pair” concept. A step-by-step description, initiating from the moment of scandium isotope production and leading up to their preclinical and clinical trial applications, is presented. Recent developments related to the nuclear reactions selected and employed to produce the radionuclides Sc-43, Sc-44, and Sc-47, the chemical processing of these isotopes and the main target recovery methods are also included. Furthermore, the radiolabeling of the leading chelator, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), and its structural analogues with scandium is also discussed and the advantages and disadvantages of scandium complexation are evaluated. Finally, a review of the preclinical studies and clinical trials involving scandium, as well as future challenges for its clinical uses and applications, are presented.

show abstract

Section: Methods For the Detection Of Scandium And Other Radionuclide...mentioning

confidence: 99%

Section: Methods For the Detection Of Scandium And Other Radionuclide...mentioning

confidence: 99%

Section: Properties and Effects Of Scandium In The Context Of Nuclear...mentioning

confidence: 99%

See 1 more Smart Citation

Towards Clinical Development of Scandium Radioisotope Complexes for Use in Nuclear Medicine: Encouraging Prospects with the Chelator 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid (DOTA) and Its Analogues

Ioannidis,

Lefkaritis,

Georgiades

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

First-in-human study of dosimetry, safety and efficacy for [177Lu]Lu-P15-073: a novel bisphosphonate-based radioligand therapy (RLT) agent for bone metastases

Zhao,

Lv,

et al. 2024

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Worldwide research trends on bone metastases of lung cancer: a bibliometric analysis

Rui,

Lu,

Wei

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

BackgroundLung cancer has the highest fatality rate among all malignancies worldwide. Within this disease, bone metastasis (BM) emerges as a particularly deleterious site of metastatic dissemination, marked by a dismal prognosis. The objective of this investigation is to shed light on the current international research efforts and the development trajectory on lung cancer BM through a bibliometric analysis (performance and visualization analysis).MethodData were obtained from the Web of Science Core Collection repository on lung cancer BM from 1 January 2012 to 1 January 2022. Subsequently, the collected data underwent scrutiny using the VOSviewer software to reveal patterns of co-authorship, co-citation, and keyword analysis, while the CiteSpace software facilitated the generation of keyword cluster maps and performed burst analyses.ResultsThe study included 327 papers of 2,154 authors, 587 organizations, and 41 countries, and explored the cooperation between them and the relationships between citations. Over the past decade, published papers showed a steady growth trend. China had the highest production with 189 papers, and USA had the highest collaboration with other countries, with 43 total link strength. Lung Cancer exhibited the highest frequency of co-cited journals, with a co-citation time of 412 and an IF/JCR partition of 6.081/Q1 in 2021. The most frequently co-cited article, authored by Tsuya A and published in Lung Cancer in 2007, amassed 70 co-citations. High-frequency keywords were categorized into four clusters: pathogenesis, treatment and clinical manifestations, prognosis, and diagnosis. In recent years, there has been a significant increase in the strong citation burst strength of keywords such as “predictor,” “skeletal-related events,” “efficacy,” “migration,” “docetaxel,” and “impact.” Lung adenocarcinoma is the most common type of tumor.ConclusionThis bibliometric study provides a comprehensive analysis of lung cancer BM in the recent 10 years. The field of early diagnosis, pathogenesis, and new treatments is entering a phase of rapid development and remains valuable for future research.

show abstract

Advancements in the development of radiopharmaceuticals for nuclear medicine applications in the treatment of bone metastases

Cited by 5 publications

References 130 publications

Towards Clinical Development of Scandium Radioisotope Complexes for Use in Nuclear Medicine: Encouraging Prospects with the Chelator 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid (DOTA) and Its Analogues

Towards Clinical Development of Scandium Radioisotope Complexes for Use in Nuclear Medicine: Encouraging Prospects with the Chelator 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid (DOTA) and Its Analogues

First-in-human study of dosimetry, safety and efficacy for [177Lu]Lu-P15-073: a novel bisphosphonate-based radioligand therapy (RLT) agent for bone metastases

Worldwide research trends on bone metastases of lung cancer: a bibliometric analysis

Contact Info

Product

Resources

About